{"id":"W3081315565","doi":"10.1016/s1470-2045(20)30447-2","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; AstraZeneca; Invitae; PharmaMar; Eisai; Pfizer","keywords":"Veliparib; Carboplatin; Oncology; Medicine; Placebo; Breast cancer; Internal medicine; BRCA mutation; Paclitaxel; Cancer; Chemotherapy; Biology; Genetics; Alternative medicine; Poly ADP ribose polymerase; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007306079,0.0003157408,0.001703268,0.00009657546,0.00009438824,0.00002350302,0.0001779365,0.0002063056,0.0003060605],"category_scores_gemma":[0.00009055214,0.000198042,0.00009749698,0.000438664,0.0003055,0.00009982499,0.00004173023,0.0007335902,0.00001488945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003013202,"about_ca_system_score_gemma":0.0006606851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001992306,"about_ca_topic_score_gemma":0.0004122219,"domain_scores_codex":[0.9976404,0.0004130554,0.0006279975,0.0004898752,0.00028578,0.0005428825],"domain_scores_gemma":[0.9983895,0.0005979164,0.000342528,0.0003104323,0.0001119687,0.0002476714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814091,0.000290731,0.0002815467,0.00006283411,0.0003294003,0.0001338397,0.001849537,0.0002994212,0.006771091,0.0001069876,0.001301746,0.007163808],"study_design_scores_gemma":[0.9863515,0.002965583,0.0001984456,0.0001257379,0.0002808673,0.0002335109,0.0003802267,0.001175484,0.0008084486,0.00006856104,0.00717814,0.000233481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9326614,0.00150152,0.0001431169,0.05608265,0.0002744309,0.006016455,0.0001025771,0.0001193509,0.003098458],"genre_scores_gemma":[0.9857097,0.0007828597,0.0002868385,0.008336835,0.001709661,0.002952509,0.00003386688,0.000048618,0.000139081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05304829,"threshold_uncertainty_score":0.8075917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07829391178294297,"score_gpt":0.3971052690556947,"score_spread":0.3188113572727517,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}